keyword
MENU ▼
Read by QxMD icon Read
search

Drug coated balloon

keyword
https://www.readbyqxmd.com/read/29770768/treatment-of-femoro-popliteal-lesions-with-scoring-and-drug-coated-balloon-angioplasty-12-month-results-of-the-dcb-trak-registry
#1
Magnus Baumhäkel, Shalva Chkhetia, Michael Kindermann
PURPOSE: Debulking strategies prior to drug-coated balloon (DCB) angioplasty were suggested to improve clinical results in femoro-popliteal lesions. Currently, there are no data regarding plaque modification with a scoring balloon with subsequent DCB-angioplasty. Recently published 6-month results of the DCB-Trak registry in patients treated with scoring-balloon angioplasty and DCB-angioplasty were promising without any safety concerns. Herein, we report the 12-month follow-up data. METHODS: In a single center registry, 29 consecutive patients with 32 femoro-popliteal lesions were treated with a scoring-balloon (VascuTrak®) and a DCB subsequently...
May 2018: Diagnostic and Interventional Radiology: Official Journal of the Turkish Society of Radiology
https://www.readbyqxmd.com/read/29754850/biologic-drug-effect-and-particulate-embolization-of-drug-eluting-stents-versus-drug-coated-balloons-in-healthy-swine-femoropopliteal-arteries
#2
Sho Torii, Kazuyuki Yahagi, Hiroyoshi Mori, Emanuel Harari, Maria E Romero, Frank D Kolodgie, Brandt Young, Anthony Ragheb, Renu Virmani, Aloke V Finn
PURPOSE: To compare the drug effect in treated vessels and downstream effects in distal skeletal muscle of drug-coated balloons (DCBs) and drug-eluting stents (DESs) in a healthy preclinical swine model. MATERIALS AND METHODS: Four groups of treated iliofemoral arteries (percutaneous transluminal angioplasty [PTA]+DES, DCB+DES, DCB+bare metal stent [BMS], and DCB alone) of 12 healthy swine were assessed, with euthanasia at 30 days. Biological drug effect was evaluated using smooth muscle cell (SMC) loss score according to both depth and circumference as well a neointimal fibrin and medial proteoglycan scores which were compared between the 4 groups...
May 10, 2018: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/29743899/drug-coated-balloon-in-superficial-femoral-artery-in-stent-restenosis
#3
REVIEW
Donato Gerardi, Arturo Alfani, Tullio Tesorio, Angelo Cioppa, Giovanni Esposito, Eugenio Stabile
The femoropopliteal artery is one of the commonest sites of involvement in peripheral artery disease (PAD) leading to intermittent claudication and/or critical limb ischemia. Endovascular therapy for superficial femoral artery (SFA) disease has been recognized as a safe and efficient therapy and is recommended by current guidelines as the first-line approach. Although the widespread use of new-generation, self-expanding, nitinol stents in SFA stenosis has reduced the shortcomings associated with plain old balloon angioplasty (POBA), lumen renarrowing at the stented (in-stent restenosis - ISR) level still represents a relevant clinical problem, because of higher risk of recurrent ISR, occlusion and surgical revascularization compared to de-novo lesions...
2018: Postępy W Kardiologii Interwencyjnej, Advances in Interventional Cardiology
https://www.readbyqxmd.com/read/29737639/current-management-of-in-stent-restenosis
#4
REVIEW
Ae Young Her, Eun Seok Shin
Despite the advent of the drug-eluting stents (DES) and improved stent design, in-stent restenosis (ISR) remains a challenging problem. The currently available options for treatment of ISR include angioplasty alone, repeat stenting with DES or drug-coated balloons. Several recent studies have compared the available options for treating ISR in an attempt to identify the preferred therapeutic strategy. In this review, we will discuss the currently available therapeutic strategies for the management of patients with ISR and the evidence supporting their use...
May 2018: Korean Circulation Journal
https://www.readbyqxmd.com/read/29731024/the-potential-effects-of-new-stent-platforms-for-coronary-revascularization-in-patients-with-diabetes
#5
REVIEW
Gustavo S Guandalini, Sripal Bangalore
Coronary artery disease in patients with diabetes mellitus (DM) is characterized by extensive atherosclerosis, longer lesions, and diffuse distal disease. Consequently, these patients have worse outcomes after coronary revascularization, regardless of the modality used. Traditionally, coronary artery bypass grafting (CABG) has been regarded as more effective than percutaneous coronary intervention (PCI) in patients with DM, likely because of more complete revascularization and protection against disease progression in the bypass segment...
May 2018: Canadian Journal of Cardiology
https://www.readbyqxmd.com/read/29730377/adventitial-drug-delivery-of-dexamethasone-to-improve-primary-patency-in-the-treatment-of-superficial-femoral-and-popliteal-artery-disease-12-month-results-from-the-dance-clinical-trial
#6
Mahmood K Razavi, Dennis Donohoe, Ralph B D'Agostino, Michael R Jaff, George Adams
OBJECTIVES: This study was designed to evaluate outcomes of adventitial dexamethasone delivery adjunctive to standard endovascular revascularization in femoropopliteal peripheral artery disease. BACKGROUND: Drug-coated balloons and drug-eluting stents improve patency of endovascular interventions with passive diffusion of antiproliferative drugs. Adventitial dexamethasone delivery targets the initial triggers of the inflammatory reaction to injury, thus potentially providing a potent antirestenotic strategy...
April 27, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29730375/twelve-month-results-from-the-first-in-human-randomized-study-of-the-ranger-paclitaxel-coated-balloon-for-femoropopliteal-treatment
#7
Sabine Steiner, Andrea Willfort-Ehringer, Horst Sievert, Volker Geist, Michael Lichtenberg, Costantino Del Giudice, Antoine Sauguet, Juan Diaz-Cartelle, Claudia Marx, Armin Ströbel, Ingolf Schult, Dierk Scheinert
OBJECTIVES: The authors sought to evaluate the performance of the Ranger paclitaxel-coated balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months. BACKGROUND: Drug-coated balloons (DCBs) are a promising endovascular treatment option for peripheral artery disease of the femoropopliteal segment, and each unique device requires dedicated clinical study. METHODS: The prospective, randomized RANGER SFA (Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries) study (NCT02013193) enrolled 105 patients with symptomatic lower limb ischemia (Rutherford category 2 to 4) and stenotic lesions in the nonstented femoropopliteal segment at 10 European centers...
April 27, 2018: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/29730237/drug-coated-balloon-in-peripheral-artery-disease
#8
REVIEW
Madhan Shanmugasundaram, Sangeetha Murugapandian, Huu Tam Truong, Kapildeo Lotun, Subhash Banerjee
Peripheral artery disease (PAD) is highly prevalent but is often underdiagnosed and undertreated. Lower extremity PAD can often be life style limiting. Revascularization in carefully selected lower extremity PAD patients improves symptoms and functional status. Surgical revascularization used to be the only available strategy, but in the recent years, endovascular strategies have gained popularity due to faster recovery times with low morbidity and mortality rates. Endovascular procedures have increased significantly in the United States in the past few years...
April 21, 2018: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://www.readbyqxmd.com/read/29695655/drug-coated-balloon-vs-conventional-balloon-angioplasty-in-dialysis-patients-with-symptomatic-femoropopliteal-disease-a-matched-comparison
#9
Hsin-Hua Chou, Hsuan-Li Huang, Chien-An Hsieh, Shih-Jung Jang, I-Shiang Tzeng, Yu-Lin Ko
BACKGROUND: Recent randomized trials have shown the treatment benefits of use of a drug-coated balloon (DCB) over conventional percutaneous transluminal angioplasty (PTA) in patients with femoropopliteal disease. However, the effectiveness and safety of DCB for dialysis patients remain unclear.Methods and Results:Consecutive dialysis patients, who underwent PTA or DCB for femoropopliteal disease, were assessed retrospectively via 2:1 propensity score matching. Effectiveness and safety endpoints, including binary restenosis, clinically driven target lesion revascularization (CD-TLR), amputations, major adverse cardiac events (MACE), and deaths, were compared between groups...
April 26, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29687699/merging-the-properties-of-a-sirolimus-coated-balloon-with-those-of-a-bioresorbable-polymer-sirolimus-eluting-stent-to-address-the-diabetes-issue-results-from-the-en-abl-multicenter-registry
#10
Luca Testa, Sameer Dani, Devang Desai, Rashmit Pandya, Pritesh Parekh, Nirav Bhalani, Arvind Sharma, Chirag Seth, Manish Doshi, Prakash Sojitra, Poonam Chodvadiya, Gopee Dutta, Francesco Bedogni
BACKGROUND: Patients with diabetes mellitus (DM) have poorer outcomes after percutaneous coronary intervention than patients without diabetes. The Abluminus DES+TM drug-eluting stent (DES) features a novel technology of fusion coating of PLLA bioresorbable polymer on both the abluminal surface of the stent and exposed parts of the balloon. AIM: To evaluate the efficacy/safety profile of the Abluminus DES+ in an all-comers population with minimal exclusion criteria and with a specific focus on diabetic patients...
April 20, 2018: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/29685691/mid-term-clinical-outcomes-after-bailout-drug-eluting-stenting-for-suboptimal-drug-coated-balloon-results-insights-from-a-milan-registry
#11
Satoru Mitomo, Richard J Jabbour, Antonio Mangieri, Marco Ancona, Damiano Regazzoli, Akihito Tanaka, Francesco Giannini, Mauro Carlino, Matteo Montorfano, Alaide Chieffo, Azeem Latib, Antonio Colombo
BACKGROUND: Drug-coated balloon (DCB) is an alternative to drug-eluting stent (DES) for the treatment of small vessel or in-stent restenosis (ISR) lesions, with bailout stenting reserved for poor results after DCB inflation (residual stenosis or dissection). Data regarding bailout stenting with DES are limited. The aim of this study was to evaluate clinical outcomes after bailout stenting with DES for suboptimal DCB results. METHODS: From June 2009 to December 2015, patients who underwent bailout DES implantation for suboptimal results after DCB (residual stenosis > 30% or type C-F dissection) in 2 high-volume centers in Italy were analyzed...
April 13, 2018: International Journal of Cardiology
https://www.readbyqxmd.com/read/29682350/swirling-flow-and-wall-shear-evaluating-the-biomimics-3d-helical-centerline-stent-for-the-femoropopliteal-segment
#12
REVIEW
Timothy M Sullivan, Thomas Zeller, Masato Nakamura, Colin G Caro, Michael Lichtenberg
The BioMimics 3D self-expanding nitinol stent represents a strategy for femoropopliteal intervention that is alternative or complementary to deployment of drug-coated stents or balloons. Whereas conventional straight stents reduce arterial curvature and disturb blood flow, creating areas of low wall shear, where neointimal hyperplasia predominantly develops, the helical centerline geometry of the BioMimics 3D maintains or imparts arterial curvature, promotes laminar swirling blood flow, and elevates wall shear to protect against atherosclerosis and restenosis...
2018: International Journal of Vascular Medicine
https://www.readbyqxmd.com/read/29673299/edge-stenosis-after-covered-stenting-for-long-superficial-femoral-artery-occlusive-disease-risk-factor-analysis-and-prevention-with-drug-coated-balloon-angioplasty
#13
Ting-Chao Lin, Chun-Yang Huang, Po-Lin Chen, Chiu-Yang Lee, Chun-Che Shih, I-Ming Chen
PURPOSE: To report a retrospective analysis of risk factors for edge restenosis after Viabahn stent-graft treatment of superficial femoral artery (SFA) occlusive disease and determine any protective effect of drug-coated balloons (DCBs) used at the time of stent-graft implantation. METHODS: Between October 2011 and July 2016, 110 patients (mean age 73.3±7.6 years; 78 men) were treated with the Viabahn stent-graft for long SFA occlusions. Thirty-eight (34.5%) patients had DCB reinforcement at the distal edge of the stent-graft...
April 1, 2018: Journal of Endovascular Therapy
https://www.readbyqxmd.com/read/29666900/polymer-free-biolimus-a9-coated-stent-for-primary-percutaneous-coronary-intervention
#14
D J H Lee, J K K Loh, F H Jafary, H H Ho, T Watson, H-P Stoll, P J L Ong
BACKGROUND: The polymer-free biolimus-A9 drug-coated stent (DCS) was reported to have superior safety and efficacy outcomes compared with a bare metal stent in the LEADERS FREE trial of high-bleeding-risk patients with acute coronary syndrome and on dual antiplatelet treatment (DAPT) for 1 month. The aim of this investigation was to evaluate the DCS in a consecutive cohort of patients with ST-elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI)...
April 17, 2018: Herz
https://www.readbyqxmd.com/read/29661987/review-of-the-latest-percutaneous-devices-in-critical-limb-ischemia
#15
REVIEW
Leila Haghighat, Sophia Elissa Altin, Robert R Attaran, Carlos Mena-Hurtado, Christopher J Regan
Critical limb ischemia (CLI) is a terminal stage of peripheral arterial disease that, in the absence of intervention, may lead to lower extremity amputation or death. Endovascular interventions have become a first-line approach to the management of CLI and have advanced considerably within the past decade. This review summarizes the types of percutaneous devices and the techniques that are available for the management of CLI and the data supporting their use. These include devices that establish and maintain vessel patency, including percutaneous transluminal angioplasty, drug-coated balloons, bare metal stents, drug-eluting stents, bioresorbable vascular scaffolds, and atherectomy; devices that provide protection from embolization; and, cell-based therapies...
April 14, 2018: Journal of Clinical Medicine
https://www.readbyqxmd.com/read/29656281/treatment-of-very-small-de-novo-coronary-artery-disease-with-2-0-mm-drug-coated-balloons-showed-1-year-clinical-outcome-comparable-with-2-0-mm-drug-eluting-stents
#16
Hui Wen Sim, Rajiv Ananthakrishna, Siew Pang Chan, Adrian F Low, Chi-Hang Lee, Mark Y Chan, Edgar L Tay, Poay Huan Loh, Koo Hui Chan, Huay Cheem Tan, Joshua P Loh
OBJECTIVE: To evaluate the 1-year clinical outcomes of patients treated with 2.0 mm drug-coated balloon (DCB) vs 2.0 mm drug-eluting stent (DES) implantation in small-caliber vessel de novo coronary artery disease (CAD). METHODS: All patients treated with 2.0 mm DCB or 2.0 mm DES for very small vessel de novo CAD from July 2014 to June 2016 were included in this study. The primary endpoint was the occurrence of target-lesion failure (TLF) and time to TLF, defined as a combination of cardiac mortality, target-vessel myocardial infarction, and target-lesion revascularization (TLR)...
April 15, 2018: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/29627791/endovascular-recanalisation-with-drug-coated-balloon-for-chronic-symptomatic-middle-cerebral-artery-total-occlusion
#17
Jun Zhang, Xiao Zhang, Jin-Ping Zhang, Ju Han
The optimal treatment for patients with chronic symptomatic middle cerebral artery (MCA) total occlusion is not well established. In addition to medical therapy, vessel recanalisation with stenting has shown much promise, especially for patients with recurrent ischemic symptoms. Nevertheless, the incidence of symptomatic in-stent restenosis (ISR) is high, and is associated with an unfavorable prognosis. Drug coated balloons (DCBs) have been proven to be effective in treating and preventing ISR. However, the feasibility of DCBs for de novo intracranial atherothrombotic stenosis has not been previously described, especially for total occlusion lesions...
April 7, 2018: Journal of Neurointerventional Surgery
https://www.readbyqxmd.com/read/29627742/successful-management-of-recurrent-iliofemoral-venous-in-stent-stenosis-isr-with-a-drug-coated-balloon-dcb
#18
Xi Xue, David W Trost, Akhilesh K Sista
No abstract text is available yet for this article.
March 29, 2018: Clinical Imaging
https://www.readbyqxmd.com/read/29622999/long-term-efficacy-of-drug-coated-balloon-for-renal-artery-in-stent-restenosis
#19
Mostafa Elwany, Gaetano Di Palma, Bernardo Cortese
No abstract text is available yet for this article.
March 2018: The Egyptian heart journal: (EHJ): official bulletin of the Egyptian Society of Cardiology
https://www.readbyqxmd.com/read/29620557/impact-of-paclitaxel-coated-balloon-versus-newer-generation-drug-eluting-stent-on-periprocedural-myocardial-infarction-in-stable-angina-patients
#20
Ae-Young Her, Yong Hoon Kim, Scot Garg, Eun-Seok Shin
OBJECTIVES: Periprocedural myocardial infarction (PMI) is reported to be associated with adverse long-term clinical outcomes. This study compared the rates of PMI following treatment of de novo coronary lesions using either a paclitaxel-coated balloon (PCB) or a newer-generation drug-eluting stent (DES). PATIENTS AND METHODS: We compared the incidence of PMI in propensity-matched patients with stable angina pectoris and single-vessel de novo coronary lesions who underwent treatment with a PCB or newer-generation DES...
April 3, 2018: Coronary Artery Disease
keyword
keyword
25326
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"